Download PDF
Thromb Haemost 2012; 108(06): 1028-1030
DOI: 10.1160/TH12-07-0513
Current Controversies
Schattauer GmbH

'Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel' – a hypothesis that remains unproven

Editorial on Serebruany: ‘Viewpoint: Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel’ (Thromb Haemost 2012; 108.6)
Karsten Schrör
1   Institut für Pharmakologie und Klinische Pharmakologie, UniversitätsKlinikum, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
› Author Affiliations
Further Information

Publication History

Received: 23 July 2012

Accepted: 25 July 2012

Publication Date:
29 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Storey RF. Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thromb Haemost 2011; 105 (Suppl. 01) S75-81.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Storey RF, Becker RC, Harrington RA. et al. Characterization of dyspnoea in PLATO study patients treated with tiagrelor or clopidogel and its association with clinical outcomes. Eur Heart J 2011; 32: 2945-2953.
    CrossrefPubMedGoogle Scholar
  • 3 Schneider DJ. Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy. J Am Coll Cardiol 2011; 57: 685-687S.
    CrossrefPubMedGoogle Scholar
  • 4 Sillen H. Cook M, Davis P. Determination of unbound ticagrelor and it active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis. J Chromat B AnalyTechnol Biomed Life Sci 2011; 879: 2315-2323.
    PubMedGoogle Scholar
  • 5 Welsh RC, Rao SV, Zeymer U. et al. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patient undergoing nonurgent percutaneous coronary intervention. The INNOVATE-PCI trial. Circ Cardiovasc Interv. 2012 Epub ahead of print
    PubMedGoogle Scholar
  • 6 Serebruany VL. Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel. Thromb Haemost 2012; 108: 1024-1027.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Mason KD, Carpinelli MR., Fletcher JI. et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186.
    CrossrefPubMedGoogle Scholar
  • 8 Toy P, Lowell C. TRALI - Definition, mechanisms, incidence and clinical relevance. Best Pract Res Clin Anaesthesiol 2007; 21: 183-193.
    CrossrefPubMedGoogle Scholar
  • 9 Toy P, Gajic O, Bacchetti P. et al. Transfusion-related acute lung injury: incidence and risk factors. Blood 2012; 119: 1757-1767.
    CrossrefPubMedGoogle Scholar
  • 10 Peter K, Schwarz M, Yläne J. et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbeta3) inhibitors. Blood 1998; 92: 3240-3249.
    PubMedGoogle Scholar
  • 11 Serebruany VL. Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical Outcomes trial?. Am Heart J 2011; 161: 1-4.
    CrossrefPubMedGoogle Scholar
  • 12 Van Giezen JJJ, Sidaway J, Glaves P. et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther 2012; 17: 164-172.
    CrossrefPubMedGoogle Scholar
  • 13 Gan L-M, Wittfl A, Emanuelsson H. et al. Adenosine may mediate tiagrelor-induced dyspnea. J Am Coll Cardiol 2012; 59: E344.
    CrossrefPubMedGoogle Scholar
  • 14 Capone ML, Tacconelli S, Sciulli MG. et al. Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol Pharmacol 2003; 16 Suppl 49-58.
    CrossrefPubMedGoogle Scholar
  • 15 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
    CrossrefPubMedGoogle Scholar
  • 16 Serebruany VL. Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105: 752-759.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Wallentin L, Becker RC, James SK. et al. The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Thromb Haemost 2011; 105: 760-762.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Ohman EM, Roe MT. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Thromb Haemost 2011; 105: 763-765.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Mahaffey KW, Wojdyla DM, Becker CK. et al. Ticagrelor compared with clopidogrel by georaphic region in the Platelet Inhibition and Patient Outcome (PLATO) trial. Circulation 2011; 124: 544-554.
    PubMedGoogle Scholar
  • 20 Kohli P, Udell JA, Murphy S. et al. Discharge aspirin dose and clinical outcome in patients with ACS: an analysis from the TRiTON-TIMI-38 study. J Am Coll Cardiol 2012; 59: E342.
    CrossrefPubMedGoogle Scholar
  • 21 Mehta SR, Tanguay JF, Eikelboom JW. et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233-1243.
    CrossrefPubMedGoogle Scholar